Impact of deprescribing intervention on potentially inappropriate medications and clinical outcomes among hospitalized older adults in Malaysia: a randomized controlled trial (REVMED RCT) protocol
Tóm tắt
Polypharmacy and the use of potentially inappropriate medications (PIMs) are prevalent among older patients admitted to hospitals, posing a heightened risk of adverse drug events. This trial aims to evaluate the effectiveness of a pharmacist-led deprescribing intervention in reducing medications, PIM and improving clinical outcomes, using the locally developed Malaysian Potentially Inappropriate Prescribing Screening tool in Older Adults (MALPIP). This is an 18-month cluster-randomized, open-label, parallel-arm controlled trial conducted at 14 public hospitals in the Perak state of Malaysia. Patients aged 60 and above, who have at least one medication and one comorbidity are eligible. A stratified-cluster randomization design is employed, with 7 hospitals assigned to the control arm and 7 hospitals assigned to the intervention arm. The MALPIP screening tool will be used in the intervention group to review the medications. If PIM is detected, the pharmacists will discuss with doctors and decide whether to stop or reduce the dose. The primary outcomes of this trial are the total number of medications and number of PIM. The secondary outcomes include fall, emergency department visits, readmissions, quality of life and mortality. Outcomes will be measured during enrolment, discharge, 6, 12, and 18 months. This REVMED trial aims to test the hypothesis that a pharmacist-led deprescribing intervention initiated in the hospital will reduce the total number of medications and PIM 18 months after hospital discharge, reducing fall, emergency department visits, readmissions, mortality and lead to improvement in quality of life. Trial findings will quantify the clinical outcomes associated with reducing medications and PIM for hospitalized older adults with polypharmacy. Trial registration number: This trial was prospectively registered at clinicaltrials.gov (NCT05875623) on the 25th of May 2023. NCT05875623 Clinicaltrials.gov URL: NCT05875623 registered on 25th July 2023.
Tài liệu tham khảo
Cheng X, Yang Y, Schwebel DC, Liu Z, Li L, Cheng P, et al. Population ageing and mortality during 1990–2017: a global decomposition analysis. PLoS Med. 2020;17: e1003138.
Chang C-T, Mohd Shariff SM, Abu Bakar NS, Ramzuzzaman NS, Lim CK, Lim EYJ, et al. Polypharmacy and potentially inappropriate medications among hospitalized older adults with COVID-19 in Malaysian tertiary hospitals. J Pharm Policy Pract. 2023;16:2.
Smaje A, Weston-Clark M, Raj R, Orlu M, Davis D, Rawle M. Factors associated with medication adherence in older patients: a systematic review. Aging Med Milton NSW. 2018;1:254–66.
Gomes D, Placido AI, Mó R, Simões JL, Amaral O, Fernandes I, et al. Daily medication management and adherence in the polymedicated elderly: a cross-sectional study in Portugal. Int J Environ Res Public Health. 2019;17:200.
Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse outcomes of polypharmacy in older people: systematic review of reviews. J Am Med Dir Assoc. 2020;21:181–7.
Chang TI, Park H, Kim DW, Jeon EK, Rhee CM, Kalantar-Zadeh K, et al. Polypharmacy, hospitalization, and mortality risk: a nationwide cohort study. Sci Rep. 2020;10:18964.
Xue L, Boudreau RM, Donohue JM, Zgibor JC, Marcum ZA, Costacou T, et al. Persistent polypharmacy and fall injury risk: the Health, Aging and Body Composition Study. BMC Geriatr. 2021;21:710.
Zaninotto P, Huang YT, Di Gessa G, Abell J, Lassale C, Steptoe A. Polypharmacy is a risk factor for hospital admission due to a fall: evidence from the English Longitudinal Study of Ageing. BMC Public Health. 2020;20:1804.
Chang C-T, Ang J-Y, Islam MA, Chan H-K, Cheah W-K, Gan SH. Prevalence of drug-related problems and complementary and alternative medicine use in Malaysia: a systematic review and meta-analysis of 37,249 older adults. Pharm Basel Switz. 2021;14:187.
Wu H, Kouladjian O’Donnell L, Fujita K, Masnoon N, Hilmer SN. Deprescribing in the older patient: a narrative review of challenges and solutions. Int J Gen Med. 2021;14:3793–807.
By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023. https://doi.org/10.1111/jgs.18372.
O’Mahony D, O’Sullivan D, Byrne S, O’Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015;44:213–8.
Omuya H, Nickel C, Wilson P, Chewning B. A systematic review of randomised-controlled trials on deprescribing outcomes in older adults with polypharmacy. Int J Pharm Pract. 2023;31:349–68.
Kimura T, Fujita M, Shimizu M, Sumiyoshi K, Bansho S, Yamamoto K, et al. Effectiveness of pharmacist intervention for deprescribing potentially inappropriate medications: a prospective observational study. J Pharm Health Care Sci. 2022;8:12.
Rieckert A, Reeves D, Altiner A, Drewelow E, Esmail A, Flamm M, et al. Use of an electronic decision support tool to reduce polypharmacy in elderly people with chronic diseases: cluster randomised controlled trial. BMJ. 2020;369: m1822.
Ibrahim K, Cox NJ, Stevenson JM, Lim S, Fraser SDS, Roberts HC. A systematic review of the evidence for deprescribing interventions among older people living with frailty. BMC Geriatr. 2021;21:258.
Lee J, Negm A, Peters R, Wong EKC, Holbrook A. Deprescribing fall-risk increasing drugs (FRIDs) for the prevention of falls and fall-related complications: a systematic review and meta-analysis. BMJ Open. 2021;11: e035978.
Ie K, Hirose M, Sakai T, Motohashi I, Aihara M, Otsuki T, et al. Protocol of a randomised controlled trial on the efficacy of medication optimisation in elderly inpatients: medication optimisation protocol efficacy for geriatric inpatients (MPEG) trial. BMJ Open. 2020;10: e041125.
Kua C-H, Yeo CYY, Tan PC, Char CWT, Tan CWY, Mak V, et al. Association of deprescribing with reduction in mortality and hospitalization: a pragmatic stepped-wedge cluster-randomized controlled trial. J Am Med Dir Assoc. 2021;22:82–9.
Kua C-H, Mak VS, Lee SWH. Perspectives of health professionals towards deprescribing practice in Asian nursing homes: a qualitative interview study. BMJ Open. 2019;9: e030106.
Kua KP, Saw PS, Lee SWH. Attitudes towards deprescribing among multi-ethnic community-dwelling older patients and caregivers in Malaysia: a cross-sectional questionnaire study. Int J Clin Pharm. 2019;41:793–803.
Chock YL, Wee YL, Gan SL, Teoh KW, Ng KY, Lee SWH. How willing are patients or their caregivers to deprescribe: a systematic review and meta-analysis. J Gen Intern Med. 2021;36:3830–40.
Department of Statistics Malaysia. My local stats perak 2019. https://www.mycensus.gov.my/index.php/125-newsletter-infographics/1653-perak-scdp#galleryc107fba492-10. Accessed 4 May 2023.
Wehling M, Burkhardt H, Kuhn-Thiel A, Pazan F, Throm C, Weiss C, et al. VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing. 2016;45:262–7.
Power and sample size. 2013.
Shafie AA, Vasan Thakumar A, Lim CJ, Luo N, Rand-Hendriksen K, Md Yusof FA. EQ-5D-5L valuation for the Malaysian population. Pharmacoeconomics. 2019;37:715–25.
Shafie AA, Hassali MA, Liau SY. A cross-sectional validation study of EQ-5D among the Malaysian adult population. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2011;20:593–600.
Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics. 2018;36:675–97.
Thillainadesan J, Gnjidic D, Green S, Hilmer SN. Impact of deprescribing interventions in older hospitalised patients on prescribing and clinical outcomes: a systematic review of randomised trials. Drugs Aging. 2018;35:303–19.
Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82:583–623.
Pruskowski JA, Springer S, Thorpe CT, Klein-Fedyshin M, Handler SM. Does deprescribing improve quality of life? A systematic review of the literature. Drugs Aging. 2019;36:1097–110.